Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKIN-CKD: Skin Sodium Accumulation in Chronic Kidney Disease
NCT07020104Recruiting
- Sponsor
- University of Amsterdam
- Start
- Jan 2025
- Primary completion
- Dec 2039
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydrochlorothiazide, spironolactone and lercanidipine in chronic kidney disease (CKD) and hypertension (HTN) (4 arms), sponsored by University of Amsterdam. Primary endpoints: Skin sodium content at baseline at 0 week, Muscle sodium content at baseline at 0 week and 5 more. Started Jan 2025; status: recruiting.
02
Drugs
hydrochlorothiazidespironolactonelercanidipine
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NCT07020104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020104.